Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 08/04/20
Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary EndpointsBusiness Wire • 07/23/20
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/05/20